ISR Immune System Regulation Holding AB (publ) has currently developed a second line of immune-activating chemical entities together with the Isomerase. The studies in the new indications will focus on TBC and cancer. Many bacteria and tumours have developed systems that help them avoid recognition and activation of the immune system. Therefore, there is a big and increasing medical need for immune stimulatory drugs. ISR-50, IP protected lead drug candidate has enhanced immune stimulatory properties currently explored in vitro and in animal models of chronic bacterial infections and cancer. With the ISR-50 program ISR will address markets with high demands and large unmet medical needs, initially targeting tuberculosis, which is a global threat estimated to affect 8.6 million cases and to cause 1.3 million deaths on an annual basis. In addition, with the ISR-50 pre-clinical development program the effects in animal models of cancer are under evaluation. The new safety/toxicity testing program for ISR-50 is expected to be completed during Second Quarter 2018. Plans to initiate a phase I safety study in humans during the fall of 2018 are under way.